Rate My Professor Jim Poli

James E. Polli, PhD, serves as Professor and Ralph F. Shangraw/Noxell Endowed Chair in Industrial Pharmacy and Pharmaceutics within the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, part of the University of Maryland, Baltimore. He earned his PhD in Pharmaceutics from the University of Michigan and his BS in Pharmacy from the Philadelphia College of Pharmacy and Science. Recognized as an MPower Professor, Dr. Polli has made substantial contributions to pharmaceutical sciences through his leadership roles, including co-Director of the FDA-funded University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) and Center for Research on Complex Generics (CRCG), as well as Director of the online Master of Science in Regulatory Science program.

Dr. Polli's primary research interests center on oral drug absorption, specifically maximizing oral bioavailability via formulation and chemical strategies and establishing public quality standards for oral dosage forms. He has mentored 25 PhD graduates and served as an editor for the journal Pharmaceutical Research for 12 years. A Fellow of the American Association of Pharmaceutical Scientists (AAPS), he has received prestigious awards such as the 2024 American Association of Colleges of Pharmacy (AACP) Volwiler Research Achievement Award, the 2022 AAPS Global Leadership Award, the 2021 TOPRA Education Award, and the American Pharmacists Association (APhA) Takeru Higuchi Research Prize. His influential publications include "Efficiency of single pharmaceutical surfactants to mimic intestinal biorelevant media solubilization and dissolution of etravirine" (2024), "Differential effects of metformin-mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans" (2022), "Dissolution-hollow fiber membrane (D-HFM) system to anticipate biopharmaceutics risk of tablets and capsules" (2023), "Prediction of food effect on in vitro drug dissolution into biorelevant media" (2022), "Evaluation of Excipient Risk in BCS Class I and III Biowaivers" (2022), "Research and Education Needs for Complex Generics" (2021), and "Lack of In Vivo Impact of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs" (2016). These works underscore his impact on biopharmaceutics, regulatory science, and generic drug development.